4,943 reports of this reaction
1.6% of all Xarelto reports
#19 most reported adverse reaction
THROMBOSIS is the #19 most commonly reported adverse reaction for Xarelto, manufactured by Janssen Pharmaceuticals, Inc.. There are 4,943 FDA adverse event reports linking Xarelto to THROMBOSIS. This represents approximately 1.6% of all 302,183 adverse event reports for this drug.
Patients taking Xarelto who experience thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOSIS is a less commonly reported adverse event for Xarelto, but still significant enough to appear in the safety profile.
In addition to thrombosis, the following adverse reactions have been reported for Xarelto:
The following drugs have also been linked to thrombosis in FDA adverse event reports:
THROMBOSIS has been reported as an adverse event in 4,943 FDA reports for Xarelto. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOSIS accounts for approximately 1.6% of all adverse event reports for Xarelto, making it a notable side effect.
If you experience thrombosis while taking Xarelto, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.